Sanofi SA SNYNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline
-
Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline
-
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
-
Scribe Therapeutics to Sell 7.15 Million Shares at $13-$15 Each in IPO
-
EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update
-
EU Seeks Views on Sanofi's Concessions to End Competition Probe
-
Sanofi Drug for Rare Neuromuscular Disease Hits Goals in Late-Stage Trial
-
Sanofi Probed by EU Over Flu Vaccine Marketing
Trading Information
- Previous Close Price
- $87.05
- Day Range
- $87.10–87.10
- 52-Week Range
- $80.74–106.34
- Bid/Ask
- $85.35 / $89.88
- Shares Outstanding
- 1.20B
- Market Cap
- $104.34B
- Volume/Avg
- 97,720 / 31,978
Key Statistics
- Price/Earnings (Normalized)
- 12.37
- Price/Sales
- 1.85
- Dividend Yield (Trailing)
- 5.56%
- Dividend Yield (Forward)
- 5.56%
- Total Yield
- 10.74%
Company Profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 74,846
- Website
- https://www.sanofi.com
Competitors
Valuation
|
Metric
|
SNYNF
|
MRK
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.37 | 42.23 | 8.79 |
Price/Book Value | 1.46 | 7.98 | 1.79 |
Price/Sales | 1.85 | 5.05 | 2.41 |
Price/Cash Flow | 7.65 | 15.18 | 9.97 |
Price/Earnings
SNYNF
MRK
PFE
Financial Strength
|
Metric
|
SNYNF
|
MRK
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.49 | 0.71 | 0.85 |
Current Ratio | 0.99 | 1.32 | 1.27 |
Interest Coverage | 8.05 | 4.28 | 2.36 |
Quick Ratio
SNYNF
MRK
PFE
Profitability
|
Metric
|
SNYNF
|
MRK
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 7.96% | 6.27% | 8.46% |
Return on Equity (Normalized) | 14.96% | 16.68% | 19.70% |
Return on Invested Capital (Normalized) | 11.28% | 9.82% | 12.66% |
Return on Assets
SNYNF
MRK
PFE
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|<hH$?RyX | LOCK|S!Z | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|$MGsfx | LOCK|by | $632B | |||
| AbbVie Inc
ABBV
| LOCK|&x>pT<B | LOCK|P> | $443B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|f$Cc<Y> | LOCK|^< | $356B | |||
| Merck & Co Inc
MRK
| LOCK|@@D%%> | LOCK|@$^ | $334B | |||
| Novartis AG ADR
NVS
| LOCK|!Tp<JFWz | LOCK|bQk | $289B | |||
| AstraZeneca PLC
AZN
| LOCK|?H$>HB%M | LOCK|!#j | $245B | |||
| Amgen Inc
AMGN
| LOCK|FRtcp?# | LOCK|NyB | $226B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|l<&>%K< | LOCK|rjb | $203B | |||
| Gilead Sciences Inc
GILD
| LOCK|V?!?<& | LOCK|$! | $171B |
United States